TI-24-009: Tribal Opioid Response
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Substance Abuse and Mental Health Services Adminis notices from 2024.
Substance Abuse and Mental Health Services Adminis offered grants of up to $1.8 million to the applicants described in the notice. It expected to make about 130 awards worth $63.0 million in total. Applications closed on July 1, 2024.
From the official notice on Grants.gov, last changed May 2, 2024. Checked November 7, 2026.
- Award ceiling$1.8 million
- Total funding$63.0 million
- Expected awards130
- Cost sharingNot required
- Funding typeGrant
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| TI-26-012 | June 16, 2026 | Closed July 16, 2026 | Closed |
Key dates
| Posted | May 2, 2024 |
|---|---|
| Deadline | July 1, 2024 |
| Archived by Grants.gov | July 31, 2024 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligibility is limited to federally recognized American Indian or Alaska Native Tribe or tribal organizations. Tribes and tribal organizations may apply individually, as a consortium, or in partnership with an Urban Indian Organization.
Is this a realistic fit?
- Past Opioid STR awards averaged $6.2 million; this notice allows up to $1.8 million per award.
- Most of the program's money (92% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
The purpose of this program is to assist in addressing the opioid overdose crisis in Tribal communities by increasing access to FDA-approved medications for the treatment of opioid use disorder (MOUD), and supporting the continuum of prevention, harm reduction, treatment, and recovery support services for opioid use disorder (OUD) and co-occurring substance use disorders.
Who has won Opioid STR grants before
From fiscal 2021 to 2025, Opioid STR (93.788) awarded $2.1 billion across 336 grant awards, an average of $6.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Ohio Department Mental Health | Ohio | 2 | $154 million |
| Pennsylvania Department of Drug and Alcohol Programs | Pennsylvania | 2 | $138 million |
| California Department of Health Care Services | California | 1 | $108 million |
| Maryland Department of Health | Maryland | 2 | $105 million |
| Delaware Department of Health and Social Services | Delaware | 2 | $104 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is TI-24-009 still open?
No. It closed on July 1, 2024.
Who can apply for Tribal Opioid Response?
Substance Abuse and Mental Health Services Adminis accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Tribal Opioid Response?
Closed July 1, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.8 million each. About $63.0 million in total across about 130 awards.
Who has won Opioid STR grants before?
The largest recipients over five fiscal years were Ohio Department Mental Health, Pennsylvania Department of Drug and Alcohol Programs, California Department of Health Care Services. The program made 336 awards worth $2.1 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)